Driscoll Kara E, Sit Dorothy K Y, Moses-Kolko Eydie L, Pinheiro Emily, Yang Amy, Ciolino Jody D, Eng Heather F, Luther James F, Clark Crystal T, Wisniewski Stephen R, Wisner Katherine L
University of Pittsburgh, Pittsburgh, PA, USA.
Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Bipolar Disord. 2017 Jun;19(4):295-304. doi: 10.1111/bdi.12500. Epub 2017 Jun 30.
We conducted a prospective naturalistic study of pregnant women with bipolar disorder (BD) to evaluate symptoms of BD across childbearing and assess whether pharmacotherapy reduced their severity.
Assessments were scheduled at 20, 30, and 36 weeks' gestation and 2, 12, 26, and 52 weeks postpartum. Symptoms were assessed using the Structured Interview Guide for the Hamilton Depression Rating Scale-Atypical Depression Supplement (SIGH-ADS) and Mania Rating Scale (MRS).
Pregnant women (N=152) with BD were evaluated; 88 women (58%) were treated and 64 untreated (42%) with psychotropic drugs during pregnancy. Among the 88 women treated, 23 (26%) discontinued their medication in the first trimester and the remaining 65 (74%) were exposed throughout pregnancy or in the second and third trimesters. More than two-thirds (73%) of the women who remained in the study took psychotropic agents postpartum. The mean scores on the SIGH-ADS were in the mild range of depressive symptoms in both the psychotropic-treated and untreated groups in both pregnancy and postpartum. The majority of women had no or few symptoms of mania. Of the pregnant women treated with psychotropic agents, 66% received a guideline-concordant drug, and 34% received either antidepressant monotherapy (for BD I) or mono- or polypharmacy with a variety of other agents.
This sample of perinatal women with BD was characterized by mild residual symptoms of depression independent of pharmacotherapy, which poses a risk for recurrence and impaired parenting. The treatment of childbearing women with BD deserves urgent clinical and research attention to improve psychiatric outcomes.
我们对患有双相情感障碍(BD)的孕妇进行了一项前瞻性自然主义研究,以评估整个生育期BD的症状,并评估药物治疗是否减轻了其严重程度。
评估安排在妊娠20、30和36周以及产后2、12、26和52周进行。使用汉密尔顿抑郁量表-非典型抑郁补充版结构化访谈指南(SIGH-ADS)和躁狂量表(MRS)评估症状。
对152名患有BD的孕妇进行了评估;88名妇女(58%)在孕期接受了精神药物治疗,64名未接受治疗(42%)。在接受治疗的88名妇女中,23名(26%)在孕早期停药,其余65名(74%)在整个孕期或孕中期和孕晚期暴露于药物。留在研究中的妇女中,超过三分之二(73%)在产后服用精神药物。在孕期和产后,接受精神药物治疗和未接受治疗的两组中,SIGH-ADS的平均得分均处于轻度抑郁症状范围内。大多数妇女没有或只有很少的躁狂症状。在接受精神药物治疗的孕妇中,66%接受了符合指南的药物,34%接受了抗抑郁单药治疗(用于BD I)或与多种其他药物联合使用的单药或多药治疗。
该样本中患有BD的围产期妇女的特点是存在与药物治疗无关的轻度抑郁残留症状,这会带来复发和育儿受损的风险。对患有BD的育龄妇女的治疗值得临床和研究给予紧急关注,以改善精神科治疗效果。